Dupilumab therapy in children aged 2-12 years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e35-e38. doi: 10.1111/jdv.19409. Epub 2023 Aug 24.

Authors

Bingjing Zhou^{1

2

3}, Cong Peng^{1

2

3}, Qiaozhi Cao^{1

2

3}, Jiayi Wang^{1

2

3}, Xiang Chen^{1

2

3}, Jie Li^{1

2

3}

Affiliations

¹ Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
² Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China.
³ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

PMID: 37565387
DOI: 10.1111/jdv.19409

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized* / therapeutic use
Child
China
Dermatitis, Atopic* / drug therapy
Double-Blind Method
Humans
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
dupilumab

Grants and funding